Aditxt, Inc.'s Subsidiary Pearsanta, Inc. Acquires MDNA Life Sciences Inc.'s Proprietary Mitomic™ Testing Platform Pioneering Early Disease and Cancer Detection in a Transaction Valued at Approximately $25 Million -January 08, 2024 at 08:37 am EST
This strategic acquisition positions Pearsanta for robust growth: expanding opportunities in women’s health, spanning endometriosis to ovarian cancer, and in men’s health starting with prostate...
Source: marketscreener.com